ANDREY GAGARIN: Open Payments
NPI 1225074123 · BROCKTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,150 in 212 payments from 18 companies in 2025. Trend: 2023 $2,001 · 2024 $2,894 · 2025 $4,150
Food & beverage: $4,015Education: $135
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 50 | $730 |
| Vanda Pharmaceuticals Inc. | 36 | $474 |
| Axsome Therapeutics, Inc. | 14 | $431 |
| Teva Pharmaceuticals USA, Inc. | 12 | $379 |
| Lundbeck LLC | 15 | $352 |
| Otsuka America Pharmaceutical, Inc. | 14 | $339 |
| ABBVIE INC. | 17 | $316 |
| Tris Pharma Inc | 16 | $279 |
| Alkermes, Inc. | 8 | $160 |
| Neurocrine BioSciences, Inc. | 6 | $140 |
Products named: CAPLYTA, REXULTI, FANAPT, Auvelity, VRAYLAR, AUSTEDO XR, Dyanavel XR, ARISTADA.
Industry payments across MA — which companies pay providers there.
